Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Non-Current Assets (2024 - 2025)

Drugs Made In America Acquisition filings provide 2 years of Non-Current Assets readings, the most recent being $239.9 million for Q4 2025.

  • Quarterly Non-Current Assets rose 43852.39% to $239.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $239.9 million through Dec 2025, up 43852.39% year-over-year, with the annual reading at $239.9 million for FY2025, 43852.39% up from the prior year.
  • Non-Current Assets hit $239.9 million in Q4 2025 for Drugs Made In America Acquisition, up from $237.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $239.9 million in Q4 2025 and bottomed at $545833.0 in Q4 2024.